Imogam market outlook strengthens on rising rabies exposure risk

The Business Research Company says the Imogam market is set to grow through 2035 as animal bite cases, rabies awareness, and healthcare capacity increase worldwide. North America is projected to hold the largest share in 2025, while travel and public health spending add to demand for rabies post-exposure treatment.

Why it matters: - Imogam is used after possible rabies exposure, so demand tracks a high-stakes public health need. - Rising bite incidents, more travel, and stronger emergency care systems can all increase use of rabies immune globulin. - The market outlook matters for hospitals, public health agencies, and suppliers of post-exposure prophylaxis products.

What happened: - The Business Research Company published The Outlook for the Imogam Global Market Report 2026, covering market size, trends, and forecasts for 2026-2035. - The report says the Imogam market expanded in the historical period because of rabies-related deaths, limited early vaccine access, reliance on passive immunity treatments, vaccination campaigns, and emergency care in hospitals. - The report expects future growth to be driven by more animal bite cases, broader rabies awareness, better emergency healthcare infrastructure, improved availability of immunoglobulin products, and higher government funding for zoonotic disease control. - North America is projected to hold the largest share of the Imogam market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The details: - Imogam is a brand of human rabies immune globulin. - The product provides passive immunity and is used in post-exposure prophylaxis to help prevent rabies after exposure. - Animal bites are a key demand driver because they can require immediate medical treatment and rabies protection before vaccine-induced immunity develops. - The report points to a September 2024 Dogster estimate that the U.S. recorded 6,000 dog bite incidents in 2023, with fatalities rising from 5 in 2022 to 15 in 2023. - Global travel is another growth factor because more people are visiting rabies-endemic areas. - The report cites UK Office for National Statistics data showing overseas visitors to the UK rose from 31.2 million in 2022 to 38.0 million in 2023. - Healthcare infrastructure growth supports the market by improving storage, access, and administration of Imogam. - The report cites UK Office for National Statistics data showing healthcare spending rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth the year before, while long-term health and social care expenditure rose 2.8% in real terms in 2022. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also includes key technologies and future trend analysis. - The Business Research Company offers a free sample report and the full report through its website. - More information is available in the free sample report and the full market report.

Between the lines: - The report frames Imogam as part of a broader shift toward rapid response treatment for zoonotic disease exposure, not just rabies alone. - Travel growth and bite incidence suggest demand is being shaped by both public health risk and movement patterns, which can make market growth less dependent on one region or one trigger. - The emphasis on infrastructure and government funding points to a market that depends on healthcare system readiness as much as on clinical need.

What's next: - The report expects continued demand growth through 2035 as bite exposure, awareness, and emergency care access improve. - Market participants will likely watch North America’s share, travel volumes, and public health spending for signs of faster adoption. - Further expansion may depend on how quickly healthcare systems can improve access to immunoglobulin products in rabies-risk settings.

The bottom line: - Imogam’s market outlook is improving because the need for immediate rabies protection is rising alongside global travel, animal bites, and stronger healthcare systems.